Small cell carcinoma (SCC) of the gallbladder is a rare disease. It is an aggressive tumor that tends to metastasis early and is associated with poor prognosis. Median overall survival is reported to be approximately 13 months. Metastatic disease has a worse prognosis, and median overall survival is reported to be approximately 4 months. A 65-year-old male patient was diagnosed with the SCC of the gallbladder and was treated with cisplatin/etoposide chemotherapy followed by radiation therapy. Here, we describe the case of the SCC of the gallbladder who survived more than 3 years followed by the review of the literatures on this disease.
INTRODUCTION
Small cell carcinoma (SCC) of the gallbladder is an uncommon and a highly aggressive malignancy that was first described by Albores-Saavedra et al. 1 in 1981. The incidence of SCC among all gallbladder cancers can be estimated at about 0.5% through Surveillance, Epidemiology, and End
Results (SEER) data. 2 SCC of the gallbladder is a disease process characterized by its insidious onset and advanced stage at presentation, therefore, surgical resection is impossible in most cases. Early metastasis to regional and distant lymph nodes, liver, and lungs are common with 66% of patients having evidence of metastatic disease at diagnosis. 3 Median overall survival is reported to be only 8 months. 3 Published treatment regimens for SCC of the gallbladder are highly variable, including surgical resection, radiation and a variety of chemotherapy regimens. But, no established standard care exists for treating SCC of the gallbladder.
We here report a rare case of the gallbladder SCC in a 65-year-old male. Treated with currently available modali- chromogranin A were negative. (Fig. 2 ) Upon these findings, the patient was diagnosed with the SCC of the gallbladder.
After the infection control using percutaneous trans-hepatic gallbladder drainage, he was treated with etoposide (100 mg/m 2 ) and cisplatin (100 mg/m 2 ) beginning on day 1 of each 21-day cycle. He received three cycles of chemotherapy, but was interrupted by the onset of biliary obstruction and sepsis. Percutaneous trans-hepatic biliary drainage and biliary stent insertion were performed for relieving obstructive jaundice (Fig. 3) . And he was administered with intravenous antibiotics (moxifloxacin 400 mg/day) in order to treat sepsis. However, since then, chemotherapy was discontinued due to the recurrent biliary obstruction and sepsis.
Then palliative radiation therapy was performed because of no response to chemotherapy. As an effect of radiation therapy, the volume of the gallbladder mass was decreased, and peri-cholecystic tumor infiltration and bile duct dilatation 
DISCUSSION
SCC of the gallbladder is a rare disease, which has a distinct clinico-pathologic entity. Several case reports have been published; however, only 74 cases have been reported in the world literature when our case is diagnosed. Out of which, 55 were clinical cases, and 19 were autopsy cases. 4, 5 This disease tends to affect an older patient population occurring at a median age of 65 years, with a female preponderance of 76%. 6 It is a disease with few well-described risk This tumor may be secretory with symptoms arising due to the production of biologically active peptides. 13 Conversely, most cases of this tumor are non-secretory or do not have overt clinical signs of peptides secretion as in our patient.
Our patient only complained non-specific gastrointestinal symptoms such as nausea, indigestion and abdominal pain.
Due to lack of systemic symptoms, SCC of the gallbladder often presents at an advanced stage with only 10% of cases confined to the gallbladder wall at the time of diagnosis.
14 Distant disease at presentation is reported as much as 75%
of the cases. The most common site of metastases is lymph nodes (70%), followed by liver (64%), and lung (10%). Here, we report a rare case of the SCC of the gallbladder with metastasis diagnosed. Our patient was treated with chemotherapy and radiation therapy after the course of chemotherapy. He was not capable of reaching complete remission, but survived 28 months although previous reported median survival of the SCC of the gallbladder with metastasis was 4 months. We recommend sequential chemotherapy with platinum agents and etoposide followed by loco-regional radiation therapy. This approach can offer hope to these rare patients and contribute to increasing survival rate.
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